CORONA REMEDIES
|
CORONA REMEDIES Last 5 Year Income Statement History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| INCOME : | ||||
| Gross Sales | ₹1,175 Cr | ₹10,371 Cr | ₹898 Cr | ₹898 Cr |
| Sales | ₹1,173 Cr | ₹10,352 Cr | ₹896 Cr | ₹896 Cr |
| Job Work/ Contract Receipts | - | - | - | - |
| Processing Charges / Service Income | ₹0.98 Cr | ₹11 Cr | ₹1.37 Cr | ₹1.37 Cr |
| Revenue from property development | - | - | - | - |
| Other Operational Income | ₹0.91 Cr | ₹7.92 Cr | ₹0.52 Cr | ₹0.52 Cr |
| Less: Excise Duty | - | - | - | - |
| Net Sales | ₹1,196 Cr | ₹10,145 Cr | ₹884 Cr | ₹884 Cr |
| EXPENDITURE : | ||||
| Increase/Decrease in Stock | ₹-24 Cr | ₹-7.78 Cr | ₹-15 Cr | ₹-15 Cr |
| Raw Material Consumed | ₹260 Cr | ₹2,276 Cr | ₹225 Cr | ₹225 Cr |
| Opening Raw Materials | ₹19 Cr | ₹256 Cr | ₹15 Cr | ₹15 Cr |
| Purchases Raw Materials | ₹109 Cr | ₹962 Cr | ₹110 Cr | ₹110 Cr |
| Closing Raw Materials | ₹26 Cr | ₹191 Cr | ₹26 Cr | ₹26 Cr |
| Other Direct Purchases / Brought in cost | ₹158 Cr | ₹1,249 Cr | ₹126 Cr | ₹126 Cr |
| Other raw material cost | - | - | - | - |
| Power & Fuel Cost | ₹6.03 Cr | ₹57 Cr | ₹3.97 Cr | ₹3.97 Cr |
| Electricity & Power | ₹6.03 Cr | ₹57 Cr | ₹3.97 Cr | ₹3.97 Cr |
| Oil, Fuel & Natural gas | - | - | - | - |
| Coals etc | - | - | - | - |
| Other power & fuel | - | - | - | - |
| Employee Cost | ₹346 Cr | ₹2,954 Cr | ₹255 Cr | ₹255 Cr |
| Salaries, Wages & Bonus | ₹328 Cr | ₹2,803 Cr | ₹242 Cr | ₹242 Cr |
| Contributions to EPF & Pension Funds | ₹10 Cr | ₹96 Cr | ₹8.89 Cr | ₹8.89 Cr |
| Workmen and Staff Welfare Expenses | ₹5.20 Cr | ₹36 Cr | ₹2.33 Cr | ₹2.33 Cr |
| Other Employees Cost | ₹2.55 Cr | ₹19 Cr | ₹1.88 Cr | ₹1.88 Cr |
| Other Manufacturing Expenses | ₹15 Cr | ₹122 Cr | ₹9.24 Cr | ₹9.24 Cr |
| Sub-contracted / Out sourced services | - | - | - | - |
| Processing Charges | - | - | - | - |
| Repairs and Maintenance | ₹3.72 Cr | ₹40 Cr | ₹3.07 Cr | ₹3.07 Cr |
| Packing Material Consumed | - | - | - | - |
| Other Mfg Exp | ₹12 Cr | ₹82 Cr | ₹6.17 Cr | ₹6.17 Cr |
| General and Administration Expenses | ₹216 Cr | ₹1,876 Cr | ₹167 Cr | ₹167 Cr |
| Rent , Rates & Taxes | ₹0.12 Cr | ₹1.25 Cr | ₹0.11 Cr | ₹0.11 Cr |
| Insurance | ₹1.46 Cr | ₹22 Cr | ₹0.56 Cr | ₹0.56 Cr |
| Printing and stationery | ₹8.03 Cr | ₹90 Cr | ₹7.57 Cr | ₹7.57 Cr |
| Professional and legal fees | ₹118 Cr | ₹987 Cr | ₹88 Cr | ₹88 Cr |
| Traveling and conveyance | ₹28 Cr | ₹228 Cr | ₹20 Cr | ₹20 Cr |
| Other Administration | ₹60 Cr | ₹549 Cr | ₹50 Cr | ₹50 Cr |
| Selling and Distribution Expenses | ₹132 Cr | ₹1,169 Cr | ₹109 Cr | ₹109 Cr |
| Advertisement & Sales Promotion | ₹105 Cr | ₹903 Cr | ₹85 Cr | ₹85 Cr |
| Sales Commissions & Incentives | ₹20 Cr | ₹206 Cr | ₹17 Cr | ₹17 Cr |
| Freight and Forwarding | ₹6.62 Cr | ₹60 Cr | ₹6.72 Cr | ₹6.72 Cr |
| Handling and Clearing Charges | - | - | - | - |
| Other Selling Expenses | - | - | - | - |
| Miscellaneous Expenses | ₹5.19 Cr | ₹151 Cr | ₹2.10 Cr | ₹2.10 Cr |
| Bad debts /advances written off | ₹0.06 Cr | ₹0.21 Cr | ₹0.19 Cr | ₹0.19 Cr |
| Provision for doubtful debts | - | - | ₹0.03 Cr | ₹0.03 Cr |
| Losson disposal of fixed assets(net) | ₹0.71 Cr | ₹12 Cr | ₹0.02 Cr | ₹0.02 Cr |
| Losson foreign exchange fluctuations | - | - | - | - |
| Losson sale of non-trade current investments | - | - | - | - |
| Other Miscellaneous Expenses | ₹4.42 Cr | ₹139 Cr | ₹1.86 Cr | ₹1.86 Cr |
| Less: Expenses Capitalised | - | - | - | - |
| Total Expenditure | ₹956 Cr | ₹8,597 Cr | ₹756 Cr | ₹756 Cr |
| Operating Profit (Excl OI) | ₹240 Cr | ₹1,547 Cr | ₹128 Cr | ₹128 Cr |
| Other Income | ₹5.93 Cr | ₹65 Cr | ₹7.05 Cr | ₹7.05 Cr |
| Interest Received | ₹4.41 Cr | ₹47 Cr | ₹5.98 Cr | ₹5.98 Cr |
| Dividend Received | - | - | - | - |
| Profit on sale of Fixed Assets | - | - | - | - |
| Profits on sale of Investments | - | - | - | - |
| Provision Written Back | ₹0.20 Cr | ₹3.46 Cr | ₹0.06 Cr | ₹0.06 Cr |
| Foreign Exchange Gains | ₹0.67 Cr | ₹4.87 Cr | ₹0.56 Cr | ₹0.56 Cr |
| Others | ₹0.65 Cr | ₹9.59 Cr | ₹0.46 Cr | ₹0.46 Cr |
| Operating Profit | ₹246 Cr | ₹1,612 Cr | ₹135 Cr | ₹135 Cr |
| Interest | ₹11 Cr | ₹144 Cr | ₹4.27 Cr | ₹4.27 Cr |
| InterestonDebenture / Bonds | - | - | - | - |
| Interest on Term Loan | ₹6.16 Cr | ₹101 Cr | ₹0.23 Cr | ₹0.23 Cr |
| Intereston Fixed deposits | - | - | ₹0.03 Cr | ₹0.03 Cr |
| Bank Charges etc | ₹2.56 Cr | ₹29 Cr | ₹1.88 Cr | ₹1.88 Cr |
| Other Interest | ₹1.88 Cr | ₹14 Cr | ₹2.12 Cr | ₹2.12 Cr |
| PBDT | ₹235 Cr | ₹1,468 Cr | ₹131 Cr | ₹131 Cr |
| Depreciation | ₹37 Cr | ₹283 Cr | ₹20 Cr | ₹20 Cr |
| Profit Before Taxation & Exceptional Items | ₹198 Cr | ₹1,185 Cr | ₹111 Cr | ₹111 Cr |
| Exceptional Income / Expenses | - | - | - | - |
| Profit Before Tax | ₹199 Cr | ₹1,185 Cr | ₹111 Cr | ₹111 Cr |
| Provision for Tax | ₹49 Cr | ₹280 Cr | ₹26 Cr | ₹26 Cr |
| Current Income Tax | ₹46 Cr | ₹224 Cr | ₹26 Cr | ₹26 Cr |
| Deferred Tax | ₹4.30 Cr | ₹91 Cr | ₹-0.32 Cr | ₹-0.32 Cr |
| Other taxes | ₹-0.75 Cr | ₹-35 Cr | - | - |
| Profit After Tax | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
| Extra items | - | - | - | - |
| Minority Interest | - | - | - | - |
| Share of Associate | - | - | - | - |
| Other Consolidated Items | - | - | - | - |
| Consolidated Net Profit | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
| Adjustments to PAT | - | - | - | - |
| Profit Balance B/F | ₹378 Cr | ₹3,058 Cr | ₹228 Cr | ₹228 Cr |
| Appropriations | ₹527 Cr | ₹3,963 Cr | ₹313 Cr | ₹313 Cr |
| General Reserves | - | - | - | - |
| Proposed Equity Dividend | - | - | - | - |
| Corporate dividend tax | - | - | - | - |
| Other Appropriation | ₹24 Cr | ₹186 Cr | ₹7.42 Cr | ₹7.42 Cr |
| Equity Dividend % | ₹73.10 | ₹37.00 | ₹27.70 | ₹27.70 |
| Earnings Per Share | ₹24.43 | ₹14.80 | ₹13.89 | ₹13.89 |
| Adjusted EPS | ₹24.43 | ₹14.80 | ₹13.89 | ₹13.89 |
Compare Income Statement of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹11,714.0 Cr | 5.7% | 8% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹448,148.0 Cr | 3.5% | -1.5% | 9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,009.0 Cr | 1.1% | -1.1% | 0.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,779.0 Cr | -0.2% | -0.3% | 35% | Stock Analytics | |
| CIPLA | ₹115,772.0 Cr | 3.1% | 1% | -11.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,616.0 Cr | 1.1% | -2.1% | -5.6% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 5.7% |
8% |
|
| SENSEX | -0.8% |
1.4% |
-6.8% |
You may also like the below Video Courses